BIA submission to the UK Secondary Capital Raising Review

  • 24 Nov 21

The BIA has responded to the UK Secondary Capital Raising Review.

In our response, we said: 

  • Despite the UK’s strength in life sciences, its public markets are not functioning as a rich source of capital to support the growth of the industry.
  • The BIA has identified pre-emption rights as a significant impediment to secondary capital raising and a barrier to greater institutional investment in the sector.
  • This slows down and increases costs of new capital raises, and in some cases can limit the quantum of attainable capital.
  • The BIA recommends that UK companies be able to pass an enduring waiver of pre-emption rights for 5 years or longer to reduce the burden on companies and facilitate more efficient and rapid secondary capital raising on UK public markets.

 

BIA submission to the UK Secondary Capital Raising Review.pdf
0.22MB

More within

Add to my favourites

Back to search results